Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

EMU078051

Sigma-Aldrich

MISSION® esiRNA

targeting mouse Srpk1

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
41105324
NACRES:
NA.51

description

Powered by Eupheria Biotech

Quality Level

100

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

GCCTAAGCCAGCTGACAAAATGTCAAAGAATAAGAAGAAGAAATTGAAGAAGAAGCAGAAGCGCCAGGCAGAATTACTAGAGAAGCGAATGCAGGAAATTGAGGAAATGGAGAAAGAGTCGGGCCCTGGGCAAAAAAGACCTAACAAGCAAGAAGAATCAGAGAGTCCTGTTGACAGACCCCTGACAGAGAACCCACCTAATAAAATGACCCAAGAGAAACTTGAAGAGTCAAATTCCATTGGCCAGGACCAGACACTCACGGAGCGTGGTGGAGAGGGTGGTGCGCCAGAGATTAATTGCAATGGAGTGATTGGAGTCGTTAATTACCCTGAGAACAGTAATAATGAGACACTGAGGCATAAAGAGGATCTGCATAATGCTAATGACTGTGATGTCCACACTTTGAAGCAGGAACCTAGTTTCCTAAACTCTTCAAATGGAGACAGCAGTCCA

Ensembl | mouse accession no.

ENSMUSG00000004865

NCBI accession no.

NM_016795

shipped in

ambient

storage temp.

−20°C

Gene Information

mouse ... SRPK1(20815) , Srpk1(20815)

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

M V Gammons et al.
British journal of cancer, 111(3), 477-485 (2014-07-11)
Current therapies for metastatic melanoma are targeted either at cancer mutations driving growth (e.g., vemurafenib) or immune-based therapies (e.g., ipilimumab). Tumour progression also requires angiogenesis, which is regulated by VEGF-A, itself alternatively spliced to form two families of isoforms, pro-

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service